Fidelity SPDR Advertisement
Home > Boards > Free Zone > Big Board Trading - Technical > *SCALPSWINGSTRADDLE* ($$$)

Pharmacyclics pullback a buying opportunity, says Credit Suisse

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
madrose1 Member Profile
Member Level 
Followed By 297
Posts 47,229
Boards Moderated 10
Alias Born 04/07/01
160x600 placeholder
S&P 500 Posts Biggest Weekly Gain Of 2014
U.S. stocks closed with solid gains Friday, leaving the S&P 500 with its largest weekly advance of the year.
Top Equities Stories Of The Day
European Markets Show Signs of Stress--2nd Update
Microsoft Gains Help Lead Tech's Advance
Treasury Bonds Pull Back for Second Straight Day
Will Free Data Become the Next Free Shipping?
Microsoft Braces for Another Nokia Hit--Earnings Preview
Procter & Gamble Looking at Margins, Brands--Earnings Preview
Pfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
madrose1 Member Level  Monday, 03/25/13 08:37:55 AM
Re: None
Post # of 647841 
Pharmacyclics pullback a buying opportunity, says Credit Suisse
Credit Suisse would use the pullback in Pharmacyclics as a buying opportunity given the multi-billion dollar potential of ibrutinib. Shares are Outperform rated with a $90 price target

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist